As over activation of Nrf2 has been linked to cancer progression as well as resistance to cancer chemotherapy, Nrf2 inhibitors may be useful in improving the efficacy of cancer therapy (Kansanen et al., 2011; Wong et al., 2016). Here, NFE2L2 is linked to cancer.